Search

Your search keyword '"Combalia, A."' showing total 50 results
Start Over Author "Combalia, A." Publisher wiley
50 results on '"Combalia, A."'

1. EORTC‐QLQ‐C30 and SKINDEX‐29 measurement of health‐related quality of life in patients with mycosis fungoides and Sézary syndrome: Real‐world data in Spanish patients (MICADOS Study)

Author

Belén Navarro Matilla, Mª del Mar Onteniente Gomis, Ramon M. Pujol Vallverdú, Andrea Combalia Escudero, Irma Zapata Paz, Cristina Muniesa Montserrat, Eva González Barca, Mercedes Morillo Andújar, Amparo Pérez Ferriols, Mª Concepción Román Curto, Ricardo Fernández de Misa Cabrera, Mercedes Hospital Gil, Ana Marín Niebla, Pablo J. Rios Rull, Fátima de laCruz Vicente, Rosa M. Izu Belloso, Alejandro Martín García‐Sancho, M. Elisabet Parera Amer, Raúl Córdoba Mascuñano, María Dolores Ramón Quiles, Ana Saus Carreres, Raquel delCampo García, Salma Machan, Pablo Viguera Ester, Julia Blanco Garnelo, Begoña Soler López, and Pablo L. Ortiz Romero

Subjects
cutaneous T‐cell lymphoma, EORTC‐QLQ‐C30, mycosis fungoides, quality of Life, Sézary Syndrome, SKINDEX‐29, Dermatology, RL1-803, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Abstract Background Few studies have explored the impact of cutaneous T‐cell lymphoma (CTCL) on health‐related quality of life (HRQoL) and compared it to other patients with cancer. Objectives The primary objective of the study was to assess the QoL of patients diagnosed with the mycosis fungoides (MF) and Sézary syndrome (SS) types of CTCL in Spain. Methods A cross‐sectional observational study was completed recruiting adult patients with MF and SS, exploring the European Organisation for Research and Treatment of Cancer‐Core Quality of Life Questionnaire, version 3 (EORTC‐QLQ‐C30v3) and Skindex‐29 HRQoL and itching intensity. Results A total of 141 patients [81 males (57.4%) and mean age of 63.6 years (95% CI: 61.4–65.7)], were included. EORTC‐QLQ‐C30 global health status showed worse scores in CTCL patients compared to healthy population (p

Published
2022
Full Text
View/download PDF

2. A lower starting point for the medial cut increases the posterior slope in opening‐wedge high tibial osteotomy: a cadaveric study

Author

Juan Ignacio Erquicia, Sergi Gil‐Gonzalez, Maximiliano Ibañez, Joan Leal‐Blanquet, Andrés Combalia, Juan Carlos Monllau, and Xavier Pelfort

Subjects
Anterior cruciate ligament, Cadaveric study, Lateral knee X‐ray, Medial starting point, Posterior tibial slope, Opening‐wedge high tibial osteotomy, Orthopedic surgery, RD701-811
Abstract

Abstract Purpose The objective of this study was to evaluate the effects on the posterior tibial slope of different distances from the joint line to start the osteotomy and of varying the placement of the opening wedge in high tibial osteotomy. Starting the osteotomy more distally and an incorrect location for the tibial opening wedge were hypothesized to increase the posterior tibial slope. Methods A cadaveric study was conducted using 12 knees divided into two groups based on the distance from the joint line to the start of the osteotomy: 3 and 4 cm. The preintervention posterior tibial slope was measured radiologically. Once the osteotomy was performed, the medial cortex of the tibia was divided into anteromedial, medial, and posteromedial thirds. A 10° opening wedge was sequentially placed in each third, and the effect on the posterior tibial slope was evaluated radiographically. Results: Significant changes were observed only in the 3‐cm group (p = 0.02) when the wedge was placed in the anteromedial zone. In contrast, in the 4‐cm group, significant differences were observed when the opening wedge was placed at both the medial (p = 0.04) and anteromedial (p = 0.012) zones. Conclusion Correct control of the posterior tibial slope can be achieved by avoiding a low point when beginning the osteotomy and placing the opening wedge in the posteromedial third of the tibia when performing an opening‐wedge high tibial osteotomy. Level of evidence Controlled laboratory study.

Published
2022
Full Text
View/download PDF

10. Brentuximab vedotin in the treatment of cutaneous T‐cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry

Author

Muniesa, Cristina, primary, Gallardo, Fernando, additional, García‐Doval, Ignacio, additional, Estrach, M. Teresa, additional, Combalia, Andrea, additional, Morillo‐Andújar, Mercedes, additional, De la Cruz‐Vicente, Fátima, additional, Machan, Salma, additional, Moya‐Martínez, Cristina, additional, Rovira, Roger, additional, Sanchez‐Gonzalez, Blanca, additional, Acebo, Elvira, additional, Amutio, Elena, additional, Peñate, Yeray, additional, Losada‐Castillo, Maria del Carmen, additional, García‐Muret, M. Pilar, additional, Iznardo, Helena, additional, Román‐Curto, Concepción, additional, Cañueto, Javier, additional, Fernández‐de‐Misa, Ricardo, additional, Flórez, Ángeles, additional, Izu, Rosa María, additional, Torres‐Navarro, Ignacio, additional, Zayas, Ana, additional, Pérez‐Paredes, Gema, additional, Blanes, Mar, additional, Yanguas, J. Ignacio, additional, Pérez‐Ferriols, Amparo, additional, Callejas‐Charavia, Marta, additional, Ortiz‐Romero, Pablo Luis, additional, Pérez‐Gil, Amalia, additional, Prieto‐Torres, Lucia, additional, González‐Barca, Eva, additional, and Servitje, Octavio, additional

Published
2022
Full Text
View/download PDF

11. EORTC‐QLQ‐C30 and SKINDEX‐29 measurement of health‐related quality of life in patients with mycosis fungoides and Sézary syndrome: Real‐world data in Spanish patients (MICADOS Study)

Author

Navarro Matilla, Belén, primary, Onteniente Gomis, Mª del Mar, additional, Pujol Vallverdú, Ramon M., additional, Combalia Escudero, Andrea, additional, Zapata Paz, Irma, additional, Muniesa Montserrat, Cristina, additional, González Barca, Eva, additional, Morillo Andújar, Mercedes, additional, Pérez Ferriols, Amparo, additional, Román Curto, Mª Concepción, additional, Fernández de Misa Cabrera, Ricardo, additional, Hospital Gil, Mercedes, additional, Marín Niebla, Ana, additional, Rios Rull, Pablo J., additional, de la Cruz Vicente, Fátima, additional, Izu Belloso, Rosa M., additional, Martín García‐Sancho, Alejandro, additional, Parera Amer, M. Elisabet, additional, Córdoba Mascuñano, Raúl, additional, Ramón Quiles, María Dolores, additional, Saus Carreres, Ana, additional, del Campo García, Raquel, additional, Machan, Salma, additional, Viguera Ester, Pablo, additional, Blanco Garnelo, Julia, additional, Soler López, Begoña, additional, and Ortiz Romero, Pablo L., additional

Published
2022
Full Text
View/download PDF

12. Developing indicators for quality assurance in cytopathology. Catalan Society of Cytopathology

Author

Joana Gallardo, Xavier Tarroch, Francesc Alameda, Carem Vasquez, Belen Lloveras, Clarisa Gonzalez, Jordi Temprana, Neus Combalia, Isabel Català, Gemma Fabra, Francisco Pérez-Ochoa, Ramon Bosch, Francisco Tresserra, Maria Santacana, Maria Carme Dinares, and Eva Mancebo

Subjects
Quality Control, Histology, Quality Assurance, Health Care, Process (engineering), Cytodiagnosis, media_common.quotation_subject, Delphi method, 030209 endocrinology & metabolism, Pathology and Forensic Medicine, Scientific evidence, 03 medical and health sciences, 0302 clinical medicine, Humans, Medicine, Quality (business), media_common, Medical education, business.industry, General Medicine, language.human_language, Cytopathology, 030220 oncology & carcinogenesis, language, Catalan, Laboratories, business, Quality assurance
Abstract

BACKGROUND Quality control in cytology must be established through reliable and easily measurable indicators. METHODS From the Catalan Society of Cytopathology a group of experts has been established to write a document with 13 indicators that cover the entire cytological process, based on its Cytopathology Quality Guide. It has been elaborated through guides and documents with scientific evidence and DELPHI methodology in order to reach a structured consensus on the opinions of a group of experts. RESULTS Thirteen indicators, covering all the cytologic process are expressed in worksheets specifying all their characteristics. CONCLUSION This document allows the control of all stages of the cytological process.

Published
2020
Full Text
View/download PDF

14. Patients with primary cutaneous lymphoma are at risk for severe COVID‐19. Data from the Spanish Primary Cutaneous Lymphoma Registry

Author

Sánchez‐Velázquez, A., primary, Bauer‐Alonso, A., additional, Estrach, T., additional, Vega‐Díez, D., additional, Garcia‐Muret, P., additional, Haya, L., additional, Peñate, Y., additional, Acebo, E., additional, Fernández de Misa, R., additional, Blanes, M., additional, Suh‐Oh, H.J., additional, Izu, R., additional, Silva‐Díaz, E., additional, Sarriugarte, J., additional, Román‐Curto, C., additional, Botella‐Estrada, R., additional, Mateu‐Puchades, A., additional, Prieto‐Torres, L., additional, Morillas, V., additional, Morillo, M., additional, Sánchez‐Caminero, P., additional, Calzado, L., additional, Pérez-Ferriols, A., additional, Pérez, A., additional, Domínguez, J.D., additional, Navedo, M., additional, Muniesa, C., additional, Combalia, A., additional, Arroyo-Andrés, J., additional, Descalzo, M.A., additional, García-Doval, I., additional, and Ortiz-Romero, P.L., additional

Published
2021
Full Text
View/download PDF

15. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study

Author

Quaglino, P, Prince, HM, Cowan, R, Vermeer, M, Papadavid, E, Bagot, M, Servitjie, O, Berti, E, Guenova, E, Stadler, R, Querfeld, C, Busschots, AM, Hodak, E, Patsatsi, A, Sanches, J, Maule, M, Yoo, J, Kevin, M, Fava, P, Ribero, S, Zocchi, L, Rubatto, M, Fierro, MT, Wehkamp, U, Marshalko, M, Mitteldorf, C, Akilov, O, Ortiz-Romero, P, Estrach, T, Vakeva, L, Enz, PA, Wobser, M, Bayne, M, Jonak, C, Rubeta, M, Forbes, A, Bates, A, Battistella, M, Amel-Kashipaz, R, Vydianath, B, Combalia, A, Georgiou, E, Hauben, E, Hong, EK, Jost, M, Knobler, R, Amitay-Laish, I, Miyashiro, D, Cury-Martins, J, Martinez, X, Muniesa, C, Prag-Naveh, H, Stratigos, A, Nikolaou, V, Quint, K, Ram-Wolff, C, Rieger, K, Stranzenbach, R, Szepesi, A, Alberti-Violetti, S, Felicity, E, Cerroni, L, Kempf, W, Whittaker, S, Willemze, R, Kim, Y, Scarisbrick, JJ, Quaglino, P, Prince, HM, Cowan, R, Vermeer, M, Papadavid, E, Bagot, M, Servitjie, O, Berti, E, Guenova, E, Stadler, R, Querfeld, C, Busschots, AM, Hodak, E, Patsatsi, A, Sanches, J, Maule, M, Yoo, J, Kevin, M, Fava, P, Ribero, S, Zocchi, L, Rubatto, M, Fierro, MT, Wehkamp, U, Marshalko, M, Mitteldorf, C, Akilov, O, Ortiz-Romero, P, Estrach, T, Vakeva, L, Enz, PA, Wobser, M, Bayne, M, Jonak, C, Rubeta, M, Forbes, A, Bates, A, Battistella, M, Amel-Kashipaz, R, Vydianath, B, Combalia, A, Georgiou, E, Hauben, E, Hong, EK, Jost, M, Knobler, R, Amitay-Laish, I, Miyashiro, D, Cury-Martins, J, Martinez, X, Muniesa, C, Prag-Naveh, H, Stratigos, A, Nikolaou, V, Quint, K, Ram-Wolff, C, Rieger, K, Stranzenbach, R, Szepesi, A, Alberti-Violetti, S, Felicity, E, Cerroni, L, Kempf, W, Whittaker, S, Willemze, R, Kim, Y, and Scarisbrick, JJ

Abstract

BACKGROUND: The PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study is a prospective analysis of an international database. Here we examine front-line treatments and quality of life (QoL) in patients with newly diagnosed mycosis fungoides (MF). OBJECTIVES: To identify (i) differences in first-line approaches according to tumour-nodes-metastasis-blood (TNMB) staging; (ii) parameters related to a first-line systemic approach and (iii) response rates and QoL measures. METHODS: In total, 395 newly diagnosed patients with early-stage MF (stage IA-IIA) were recruited from 41 centres in 17 countries between 1 January 2015 and 31 December 2018 following central clinicopathological review. RESULTS: The most common first-line therapy was skin-directed therapy (SDT) (322 cases, 81·5%), while a smaller percentage (44 cases, 11·1%) received systemic therapy. Expectant observation was used in 7·3%. In univariate analysis, the use of systemic therapy was significantly associated with higher clinical stage (IA, 6%; IB, 14%; IIA, 20%; IA-IB vs. IIA, P < 0·001), presence of plaques (T1a/T2a, 5%; T1b/T2b, 17%; P < 0·001), higher modified Severity Weighted Assessment Tool (> 10, 15%; ≤ 10, 7%; P = 0·01) and folliculotropic MF (FMF) (24% vs. 12%, P = 0·001). Multivariate analysis demonstrated significant associations with the presence of plaques (T1b/T2b vs. T1a/T2a, odds ratio 3·07) and FMF (odds ratio 2·83). The overall response rate (ORR) to first-line SDT was 73%, while the ORR to first-line systemic treatments was lower (57%) (P = 0·027). Health-related QoL improved significantly both in patients with responsive disease and in those with stable disease. CONCLUSIONS: Disease characteristics such as presence of plaques and FMF influence physician treatment choices, and SDT was superior to systemic therapy even in patients with such disease characteristics. Consequently, future treatment guidelines for early-stage MF need to address these issues.

Published
2021

17. Influence of germline genetic variants on dermoscopic features of melanoma

Author

Pozzobon, Flavia Carolina, primary, Tell‐Marti, Gemma, additional, Calbet‐Llopart, Neus, additional, Barreiro, Alicia, additional, Espinosa, Natalia, additional, Potrony, Míriam, additional, Alejo, Beatriz, additional, Podlipnik, Sebastian, additional, Combalia, Marc, additional, Puig‐Butillé, Joan Anton, additional, Carrera, Cristina, additional, Malvehy, Josep, additional, and Puig, Susana, additional

Published
2021
Full Text
View/download PDF

18. Developing indicators for quality assurance in cytopathology. Catalan Society of Cytopathology

Author

Tresserra, Francisco, primary, Temprana, Jordi, additional, Vasquez, Carem, additional, Lloveras, Belen, additional, Català, Isabel, additional, Tarroch, Xavier, additional, Combalia, Neus, additional, Alameda, Francesc, additional, Bosch, Ramon, additional, Gallardo, Joana, additional, Mancebo, Eva, additional, Fabra, Gemma, additional, Dinares, Maria Carme, additional, Santacana, Maria, additional, Gonzalez, Clarisa, additional, and Pérez‐Ochoa, Francisco, additional

Published
2020
Full Text
View/download PDF

20. Clinical and photobiological response in eight patients with solar urticaria under treatment with omalizumab, and review of the literature

Author

Paula Aguilera, Sebastian Podlipnik, Daniel Morgado-Carrasco, Xavier Fustà-Novell, and Andrea Combalia

Subjects
Adult, Male, medicine.medical_specialty, Urticaria, Visual analogue scale, Immunology, Solar urticaria, Photodermatosis, Omalizumab, Dermatology, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Refractory, medicine, Humans, Immunology and Allergy, Radiology, Nuclear Medicine and imaging, Physical urticaria, business.industry, General Medicine, Dermatology Life Quality Index, Middle Aged, medicine.disease, 030228 respiratory system, Sunlight, Phototesting, Female, business, medicine.drug
Abstract

BACKGROUND Solar urticaria (SU) is a rare photodermatosis. Treatment is challenging, and outcomes are often disappointing. Omalizumab is an anti-IgE, currently approved for treatment of chronic spontaneous urticaria. We sought to evaluate therapy with omalizumab in refractory SU and describe predictive factors for response. MATERIALS/METHODS Patients with refractory SU under treatment with omalizumab were included in this study. Clinical outcome was evaluated using the Urticaria Activity Score 7 (UAS7), Dermatology Life Quality Index (DLQI) and Pruritus Visual Analogue Scale (VAS). Complete clinical response (CCR) was defined as having an UAS7 = 0, DLQI

Published
2018
Full Text
View/download PDF

21. Porokeratosis ptychotropica responding to photodynamic therapy: An alternative treatment for a refractory disease

Author

Xavier Fustà-Novell, Paula Aguilera, Juan Ferrando, José M. Mascaró, Daniel Morgado-Carrasco, Andrea Combalia, and Sebastian Podlipnik

Subjects
Male, medicine.medical_specialty, Intergluteal cleft, medicine.medical_treatment, Immunology, Hyperkeratosis, Photodynamic therapy, Dermatology, Disease, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, Immunology and Allergy, Radiology, Nuclear Medicine and imaging, Photosensitizing Agents, business.industry, Pruritus, Aminolevulinic Acid, General Medicine, Middle Aged, medicine.disease, Symptomatic relief, Alternative treatment, Porokeratosis, Photochemotherapy, 030220 oncology & carcinogenesis, Retreatment, Itching, medicine.symptom, business
Abstract

Background Porokeratosis ptychotropica (PP) is a rare variant of porokeratosis with a special predisposition to affect body folds, particularly the intergluteal cleft. This disease is resistant to most topical and systemic treatments reported, as shown in the review of the literature we provide here. Itching and discomfort are often a difficult problem to solve. Patients and Methods Two patients with PP that had not responded to multiple topical treatments were treated with photodynamic therapy (PDT). Changes in plaque size, thickness, and symptoms were assessed after treatment. Results Pruritus disappearance was observed in both patients after treatment with PDT. Partial clearance of the plaques was observed in one case. In the other case, a moderate clearance of hyperkeratosis was observed, though the size of the lesions persisted unchanged. Conclusions PDT seems to be a good therapeutic alternative in the treatment of PP, as it can provide symptomatic relief and clinical improvement of the lesions. However, it does not appear to be a curative treatment. Moreover, long-term response is still unknown. This article is protected by copyright. All rights reserved.

Published
2017
Full Text
View/download PDF

22. Prognostic factors in patients with primary cutaneous anaplastic large cell lymphoma: a multicentric, retrospective analysis of the Spanish Group of Cutaneous Lymphoma

Author

F. Gallardo, Buenaventura Hernández-Machín, A. Pérez Gil, Andrea Combalia, R. Izu, R.M. Pujol, Cristina Muniesa, M P García Muret, Javier Cañueto, Jesús Bastida, Ricardo Fernández-de-Misa, L. Blanch Rius, M. Morillo, Lidia Maroñas-Jiménez, Pablo L. Ortiz-Romero, Yeray Peñate, Ariadna Ortiz-Brugués, Rosa M. Martí, M. Blanes, P. Espinosa Lara, S. Pérez Gala, Teresa Estrach, Octavio Servitje, and Concepción Román

Subjects
Male, medicine.medical_specialty, CD30, medicine.medical_treatment, Primary cutaneous anaplastic large cell lymphoma, Dermatology, Gastroenterology, Cutaneous lymphoma, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Lymphoma, Primary Cutaneous Anaplastic Large Cell, hemic and lymphatic diseases, Internal medicine, medicine, Humans, In patient, Neoplasm Staging, Retrospective Studies, Chemotherapy, business.industry, Large cell, Middle Aged, medicine.disease, Prognosis, Lymphoma, Radiation therapy, Survival Rate, Infectious Diseases, Spain, 030220 oncology & carcinogenesis, Lymphatic Metastasis, Disease Progression, Female, business
Abstract

BACKGROUND Reliable prognostic factors for patients with primary cutaneous anaplastic large cell lymphoma (PCALCL) are lacking. OBJECTIVE To identify prognostic factors for specific survival in patients with PCALCL. METHODS Using the convenience sampling method, patients with PCALCL diagnosed from May 1986 to August 2017 in 16 University Departments were retrospectively reviewed. RESULTS One hundred eight patients were included (57 males). Median age at diagnosis was 58 years. All of them showed T1-3N0M0 stages. Seventy per cent of the cases presented with a solitary lesion, mostly at the limbs. Complete response rate after first-line treatment was 87%, and no advantage was observed for any of them (surgery, radiotherapy, chemotherapy or other approaches). Nodal and visceral progression rate was 11% and 2%, respectively. 5-year specific survival (SSV) reached 93%; 97% for T1 patients and 84% for T2/T3 patients (P = 0.031). Five-year SSV for patients developing early cutaneous relapse was 64%; for those with late or no relapse, 96% (P = 0.001). Estimated median SSV for patients showing nodal progression was 103 months (95% CI: 51-155 months); for patients without nodal progression, estimated SSV did not reach the median (P

Published
2020

23. Hedgehog‐like moustache trichomegaly during treatment with vismodegib

Author

A. Rodríguez, J. Ferrando, J. Riera-Monroig, Llucia Alos, C. Mangas, Cristina Carrera, and Andrea Combalia

Subjects
medicine.medical_specialty, business.industry, Vismodegib, Dermatology, Infectious Diseases, medicine.anatomical_structure, Medicine, Trichomegaly, medicine.symptom, business, Moustache, Hedgehog, medicine.drug
Published
2019
Full Text
View/download PDF

24. Demodicosis in two patients with a previous history of Langerhans cell histiocytosis

Author

Asunción Vicente, María Antonia González-Enseñat, Marcial Álvarez-Salafranca, Andrea Combalia, Carolina Prat Torres, Veronica Paola Celis-Passini, and Manuel Monsonís

Subjects
Male, Mite Infestations, 030213 general clinical medicine, medicine.medical_specialty, Systemic disease, Langerhans cell, medicine.medical_treatment, Antineoplastic Agents, Dermatology, Immunocompromised Host, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Anti-Infective Agents, Langerhans cell histiocytosis, Metronidazole, medicine, Demodicosis, Animals, Humans, Mites, Chemotherapy, business.industry, Infant, food and beverages, medicine.disease, Histiocytosis, Langerhans-Cell, Histiocytosis, medicine.anatomical_structure, Child, Preschool, Pediatrics, Perinatology and Child Health, Demodex mites, Female, business, medicine.drug
Abstract

Demodex mites are commensal organisms rarely found in healthy children. Human demodicosis can be classified as a primary or a secondary form. The secondary form in children usually affects severely immunodepressed children. To our knowledge, this is the first report of human demodicosis associated with Langerhans cell histiocytosis. These cases show that this skin disorder can occur months after completing chemotherapy, without recurrence of the systemic disease.

Published
2017
Full Text
View/download PDF

26. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients

Author

Scarisbrick, JJ, Quaglino, P, Prince, HM, Papadavid, E, Hodak, E, Bagot, M, Servitje, O, Berti, E, Ortiz-Romero, P, Stadler, R, Patsatsi, A, Knobler, R, Guenova, E, Child, F, Whittaker, S, Nikolaou, V, Tomasini, C, Amitay, I, Prag Naveh, H, Ram-Wolff, C, Battistella, M, Alberti-Violetti, S, Stranzenbach, R, Gargallo, V, Muniesa, C, Koletsa, T, Jonak, C, Porkert, S, Mitteldorf, C, Estrach, T, Combalia, A, Marschalko, M, Csomor, J, Szepesi, A, Cozzio, A, Dummer, R, Pimpinelli, N, Grandi, V, Beylot-Barry, M, Pham-Ledard, A, Wobser, M, Geissinger, E, Wehkamp, U, Weichenthal, M, Cowan, R, Parry, E, Harris, J, Wachsmuth, R, Turner, D, Bates, A, Healy, E, Trautinger, F, Latzka, J, Yoo, J, Vydianath, B, Amel-Kashipaz, R, Marinos, L, Oikonomidi, A, Stratigos, A, Vignon-Pennamen, M-D, Climent, F, Gonzalez-Barca, E, Georgiou, E, Senetta, R, Zinzani, P, Vakeva, L, Ranki, A, Busschots, A-M, Hauben, E, Bervoets, A, Woei-A-Jin, FJSH, Matin, R, Collins, G, Weatherhead, S, Frew, J, Bayne, M, Dunnill, G, McKay, P, Arumainathan, A, Azurdia, R, Benstead, K, Twigger, R, Rieger, K, Brown, R, Sanches, JA, Miyashiro, D, Akilov, O, McCann, S, Sahi, H, Damasco, FM, Querfeld, C, Folkes, A, Bur, C, Klemke, C-D, Enz, P, Pujol, R, Quint, K, Geskin, L, Hong, E, Evison, F, Vermeer, M, Cerroni, L, Kempf, W, Kim, Y, Willemze, R, Scarisbrick, JJ, Quaglino, P, Prince, HM, Papadavid, E, Hodak, E, Bagot, M, Servitje, O, Berti, E, Ortiz-Romero, P, Stadler, R, Patsatsi, A, Knobler, R, Guenova, E, Child, F, Whittaker, S, Nikolaou, V, Tomasini, C, Amitay, I, Prag Naveh, H, Ram-Wolff, C, Battistella, M, Alberti-Violetti, S, Stranzenbach, R, Gargallo, V, Muniesa, C, Koletsa, T, Jonak, C, Porkert, S, Mitteldorf, C, Estrach, T, Combalia, A, Marschalko, M, Csomor, J, Szepesi, A, Cozzio, A, Dummer, R, Pimpinelli, N, Grandi, V, Beylot-Barry, M, Pham-Ledard, A, Wobser, M, Geissinger, E, Wehkamp, U, Weichenthal, M, Cowan, R, Parry, E, Harris, J, Wachsmuth, R, Turner, D, Bates, A, Healy, E, Trautinger, F, Latzka, J, Yoo, J, Vydianath, B, Amel-Kashipaz, R, Marinos, L, Oikonomidi, A, Stratigos, A, Vignon-Pennamen, M-D, Climent, F, Gonzalez-Barca, E, Georgiou, E, Senetta, R, Zinzani, P, Vakeva, L, Ranki, A, Busschots, A-M, Hauben, E, Bervoets, A, Woei-A-Jin, FJSH, Matin, R, Collins, G, Weatherhead, S, Frew, J, Bayne, M, Dunnill, G, McKay, P, Arumainathan, A, Azurdia, R, Benstead, K, Twigger, R, Rieger, K, Brown, R, Sanches, JA, Miyashiro, D, Akilov, O, McCann, S, Sahi, H, Damasco, FM, Querfeld, C, Folkes, A, Bur, C, Klemke, C-D, Enz, P, Pujol, R, Quint, K, Geskin, L, Hong, E, Evison, F, Vermeer, M, Cerroni, L, Kempf, W, Kim, Y, and Willemze, R

Abstract

BACKGROUND: Survival in mycosis fungoides (MF) is varied and may be poor. The PROCLIPI (PROspective Cutaneous Lymphoma International Prognostic Index) study is a web-based data collection system for early-stage MF with legal data-sharing agreements permitting international collaboration in a rare cancer with complex pathology. Clinicopathological data must be 100% complete and in-built intelligence in the database system ensures accurate staging. OBJECTIVES: To develop a prognostic index for MF. METHODS: Predefined datasets for clinical, haematological, radiological, immunohistochemical, genotypic, treatment and quality of life are collected at first diagnosis of MF and annually to test against survival. Biobanked tissue samples are recorded within a Federated Biobank for translational studies. RESULTS: In total, 430 patients were enrolled from 29 centres in 15 countries spanning five continents. Altogether, 348 were confirmed as having early-stage MF at central review. The majority had classical MF (81·6%) with a CD4 phenotype (88·2%). Folliculotropic MF was diagnosed in 17·8%. Most presented with stage I (IA: 49·4%; IB: 42·8%), but 7·8% presented with enlarged lymph nodes (stage IIA). A diagnostic delay between first symptom development and initial diagnosis was frequent [85·6%; median delay 36 months (interquartile range 12-90)]. This highlights the difficulties in accurate diagnosis, which includes lack of a singular diagnostic test for MF. CONCLUSIONS: This confirmed early-stage MF cohort is being followed-up to identify prognostic factors, which may allow better management and improve survival by identifying patients at risk of disease progression. This study design is a useful model for collaboration in other rare diseases, especially where pathological diagnosis can be complex.

Published
2019

27. Yellow urticaria: report of two cases and review of the literature

Author

José M. Mascaró, Andrea Combalia, X. Fustà, Antonio Guilabert, and Teresa Estrach

Subjects
Dermal edema, medicine.medical_specialty, Pathology, integumentary system, medicine.diagnostic_test, business.industry, Erythematous papule, Physical examination, Dermatology, Extravasation, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Infectious Diseases, medicine.anatomical_structure, Dermis, Biopsy, Skin biopsy, Medicine, Medical history, 030212 general & internal medicine, business
Abstract

Urticaria is a common skin disease characterized by transient appearance of itchy smooth and slightly elevated erythematous papules or plaques (wheals). It results from transient extravasation of plasma into the dermis that leads to dermal edema. By definition, individual lesions resolve without scarring in less than 24 hours. The diagnosis is based on detailed patient history and physical examination and skin biopsy is rarely required to confirm the diagnosis. This article is protected by copyright. All rights reserved.

Published
2016
Full Text
View/download PDF

28. Ursodeoxycholic acid decreases bilirubin-induced osteoblast apoptosis

Author

Pilar Peris, Ana Monegal, Andrés Combalia, Silvia Ruiz-Gaspà, Marta Dubreuil, Núria Guañabens, and Albert Parés

Subjects
Cholagogues and Choleretics, medicine.medical_specialty, Lithocholic acid, Bilirubin, Detergents, Clinical Biochemistry, Apoptosis, Biology, Biochemistry, Antioxidants, chemistry.chemical_compound, Cell Line, Tumor, Internal medicine, Bone cell, medicine, Humans, bcl-2-Associated X Protein, Osteoblasts, Ursodeoxycholic Acid, Osteoblast, General Medicine, Antineoplastic Agents, Phytogenic, Ursodeoxycholic acid, Up-Regulation, Endocrinology, medicine.anatomical_structure, chemistry, DNA fragmentation, Camptothecin, Lithocholic Acid, medicine.drug
Abstract

Background Low bone turnover osteoporosis is common in cholestatic diseases. Ursodeoxycholic acid (UDCA) counteracts the damaging effects of bilirubin or lithocholic acid (LCA) on osteoblast viability, proliferation and mineralisation. UDCA is anti-apoptotic in various cell lines, but this effect in bone cells is unknown. Therefore, the consequences of bilirubin and LCA on apoptosis, and whether UDCA has anti-apoptotic effects have been assessed on osteoblasts. Materials and Methods Human osteoblasts (hOB) and osteosarcoma cell line (Saos-2) were treated with camptothecin as a pro-apoptotic agent, and UDCA, LCA and bilirubin. Apoptosis was determined by DNA fragmentation, flow cytometry, caspase-3 activity and expression of pro-apoptotic (Bcl-2-associated X protein BAX) and anti-apoptotic (BCL2 and BCL2-like 1 protein, BCL2L) genes. Results Both LCA (10 μM) and bilirubin (50 μM) induced apoptosis as indicated by DNA fragmentation (4·7- and 3·7-fold, respectively, P

Published
2014
Full Text
View/download PDF

31. Reflectance confocal microscopy evaluation of trichobacteriosis axilaris

Author

Susana Puig, Andrea Combalia, and Beatriz Alejo

Subjects
Reflectance confocal microscopy, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Infectious Diseases, business.industry, Confocal, Microscopy, Medicine, 030212 general & internal medicine, Dermatology, business, Biomedical engineering
Published
2018
Full Text
View/download PDF

32. Isolated cutaneous lymphomatous form of adult T‐cell leukaemia/lymphoma

Author

Adriana García-Herrera, Andrea Combalia, Teresa Estrach, Alex Bataller, and Estella Matutes

Subjects
Male, Skin Neoplasms, Prednisolone, Adult T-cell leukaemia/lymphoma, Hematology, Middle Aged, Biology, Fatal Outcome, Doxorubicin, Vincristine, Antineoplastic Combined Chemotherapy Protocols, Cancer research, Humans, Leukemia-Lymphoma, Adult T-Cell, Cyclophosphamide
Published
2019
Full Text
View/download PDF

35. Diagnostic efficacy of bone scintigraphy, magnetic resonance imaging, and positron emission tomography in bone metastases of myxoid liposarcoma

Author

J. Marruecos, Andreu Combalia-Aleu, Joan Maurel, Mauricio Vargas, Luis Colomo, Carlos Conill, Jaime Pomes, Xavier Setoain, and Antonio Palacín

Subjects
Adult, Male, Myxoid liposarcoma, medicine.medical_specialty, medicine.diagnostic_test, business.industry, Soft tissue sarcoma, Soft tissue, Bone Neoplasms, Soft Tissue Neoplasms, Magnetic resonance imaging, medicine.disease, Magnetic Resonance Imaging, Primary tumor, Liposarcoma, Myxoid, Bone scintigraphy, Fluorodeoxyglucose F18, Positron emission tomography, Positron-Emission Tomography, Biopsy, medicine, Humans, Radiology, Nuclear Medicine and imaging, Radiology, business
Abstract

Myxoid liposarcomas (MLS) have a tendency to metastasize to unusual sites. We report an unusual case of bone metastases not detected by bone scan and neither by fluorodeoxyglucose positron emission tomography (PET-FDG) and successfully identified with magnetic resonance imaging (MRI) in a patient with metachronic MLS. Histopathological examination of the primary tumor evidenced a tumor with unfavorable prognostic markers, and the biopsy of an iliac bone lesion confirmed the diagnosis of metastatic disease. On histological grounds, the tumor showed features of a more differentiated neoplasm without foci of round cells or necrosis in the latter. MRI allowed the identification of disseminated disease compared to computed tomography (CT) and PET scans. Thus, because of the heterogeneous histological features of MLS and the biolog-ical behavior of the disease, a combined approach of FDGPET-CT and MRI, may allow a more accurate staging of soft tissue sarcomas. J. Magn. Reson. Imaging 2008;27:625–628. © 2008 Wiley-Liss, Inc.

Published
2008
Full Text
View/download PDF

39. Fine-needle aspiration cytology diagnosis of metastatic gastrointestinal stromal tumor in the liver: A report of three cases

Author

August Vidal, C T Lluis Garcia, Isabel Catala, C T Catalina Padilla, F. Javier Andreu, C T Filomena Tolosa, Amparo Saez, and Neus Combalia

Subjects
Pathology, medicine.medical_specialty, Histology, biology, GiST, business.industry, CD117, Immunocytochemistry, CD34, General Medicine, medicine.disease, digestive system diseases, Pathology and Forensic Medicine, Interstitial cell of Cajal, Metastasis, symbols.namesake, Cytopathology, symbols, biology.protein, Medicine, Stromal tumor, business, neoplasms
Abstract

Gastrointestinal stromal tumor (GIST) is the designation for a major subset of gastrointestinal mesenchymal tumors that histologically, immunocytochemically, and genetically differ from leiomyomas, leiomyosarcomas, and schwannomas. GISTs derive from the interstitial cells of Cajal and, in addition to variable expression of smooth muscle and neural markers, they characteristically express CD34 and CD117. The cytological appearance, including immunocytochemical and mutational analysis of c-kit gene in primary GIST has been well described. To our knowledge, only two cases of metastatic GIST diagnosed by fine-needle aspiration (FNA) have been reported. We illustrate three cases of metastatic GIST in the liver. Two cases had no prior history of gastrointestinal tumor and the third case had a 4-yr previous history of duodenal tumor. Consistent immunocytochemistry and ultrastructual studies supported the diagnosis of GIST. We emphasize that in the appropriate clinical and radiological setting, a confident diagnosis of GIST can be established by FNA of metastatic lesions. Diagn. Cytopathol. 2002;27:298–302. © 2002 Wiley-Liss, Inc.

Published
2002
Full Text
View/download PDF

40. Hyperbilirubinaemia: the common denominator of yellow urticaria

Author

Teresa Estrach, Andrea Combalia, X. Fustà, Antonio Guilabert, and Jr Jm Mascaró

Subjects
medicine.medical_specialty, Cirrhosis, Urticaria, business.industry, education, Common denominator, Dermatology, Disease, medicine.disease, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Infectious Diseases, Immunology, medicine, Humans, 030212 general & internal medicine, business, Hyperbilirubinemia
Abstract

Rosso et al recently enlarged to ten the list of patients diagnosed with yellow urticaria (YU). These cases of YU remind clinicians that the skin, besides forming a biological barrier to protect internal organs and systems from the external environment, frequently reflects underlying internal diseases. YU has been described secondary to infective hepatitis1, liver cirrhosis (regardless of the cause) 2, 3, 4, 5, 6, acute liver failure7, and metastatic disease of the liver8. This article is protected by copyright. All rights reserved.

Published
2017
Full Text
View/download PDF

42. Metaplastic Carcinoma of the Breast: A Cytopathologic and Immunochemical Study

Author

J. Gallardo, R. Bella, F. J. Andreu, M. A. Cabezuelo, M. Rey, N. Combalia, J. C. Ferreres, and A. Ferran

Subjects
Oncology, Metaplasia, medicine.medical_specialty, Pathology, Histology, business.industry, Cytodiagnosis, Metaplastic carcinoma, Breast Neoplasms, General Medicine, medicine.disease, Pathology and Forensic Medicine, Immunoenzyme Techniques, Internal medicine, medicine, Humans, Female, business, Aged
Published
1994
Full Text
View/download PDF

45. Lithocholic acid downregulates vitamin D effects in human osteoblasts

Author

Ruiz-Gaspà, S., primary, Guañabens, N., additional, Enjuanes, A., additional, Peris, P., additional, Martinez-Ferrer, A., additional, Martinez de Osaba, M. J., additional, Gonzalez, B., additional, Alvarez, L., additional, Monegal, A., additional, Combalia, A., additional, and Parés, A., additional

Published
2010
Full Text
View/download PDF

50. Safe drilling angles avoid femoral tunnel complications during combined anterolateral ligament and anterior cruciate ligament reconstruction.

Author

Jette C, Pomés J, Sastre S, Gutierrez D, Llusa M, and Combalia A

Subjects
Aged, Anterior Cruciate Ligament diagnostic imaging, Arthroscopy, Cadaver, Female, Femur diagnostic imaging, Humans, Male, Tomography, X-Ray Computed, Anterior Cruciate Ligament Reconstruction methods, Femur surgery, Intraoperative Complications prevention & control, Ligaments, Articular surgery
Abstract

Purpose: To determine the best angle to drill the femoral tunnels of an anterolateral ligament (ALL) anatomic reconstruction combined with a single-bundle anterior cruciate ligament (ACL) reconstruction to avoid tunnel collisions and cortical disruption., Methods: Ten cadaveric knees were studied. Single-bundle anatomic ACL femoral tunnels were arthroscopically drilled. The starting point of the ALL femoral tunnel was located posterior and superior to the lateral epicondyle. ALL tunnels were drilled at four different angulations: (1) 0° axial/0° coronal, (2) 0° axial/30° coronal superior, (3) 30° axial anterior/0° coronal, and (4) 30° axial anterior 30° coronal superior. Specimens were scanned by computed tomography to measure the relations of each trajectory with the ACL socket and the nearest cortical bone., Results: None of the four trajectories studied presented risk of collision with the ACL. The tunnel at 30° anterior/30° proximal presented the safest distance to the ACL socket (P = 0.01) [mean distance 18.6 mm (SD ± 6.7)]. However, both tunnels angled at 0° in the axial plane presented a high risk of posterior femoral cortex disruption (P = 0.01), either by close proximity or direct contact in some specimens (mean distance 3.1 mm (SD ± 2.8) at 0° axial/0° coronal and 3.7 mm (SD ± 2.2) at 0° axial/30° coronal)., Conclusions: When performing simultaneous ACL and ALL ligament reconstruction, the ALL femoral tunnel should be drilled with an angle of 30° anterior in the axial plane and 30° proximal in the coronal plane. Tunnels with an angle of 0° in the axial plane showed high risk of contact and disruption of the posterior femoral cortex; thus, these angles should be avoided. The clinical relevance of this work is that an ALL anatomical reconstruction does not represent a risk when performing a simultaneous ACL reconstruction as long as the ALL tunnel is reamed with a proximal and anterior angulation.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results